drugset / Trial / NCT02992977
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
Timeline
- Start
- 2017-01
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AutoSynVax™ | Vaccine | 240 ug | Subcutaneous |
| Subject | AutoSynVax™ vaccine | Vaccine | 240 ug | Subcutaneous |
| Background | QS-21 | Other / unclassified | 50 ug | Subcutaneous |
Indications
No indication recorded.